Certara, Inc. Common Stock
CERTCertara, Inc. is a global provider of modeling, simulation, and consulting services to the pharmaceutical, biotechnology, and regulatory communities. The company specializes in drug development, medical device development, and regulatory science, offering software and expertise to optimize clinical trials and accelerate the path to market for healthcare products.
Company News
Kopion Asset Management purchased 327,064 additional shares of Certara (worth ~$3.37 million) during Q4, despite the stock falling 23% post-earnings. The fund views the sharp decline as a buying opportunity, noting that Certara's underlying business remains solid with 10% revenue growth and improved profitability, making it an attractive entry po...
Certara announced Jon Resnick will become CEO on January 1, 2026, succeeding William Feehery. Resnick brings over 20 years of experience from IQVIA and previously worked in healthcare policy, bringing leadership expertise in health sciences and business operations.
The global In Silico Clinical Trials Market is projected to grow from $3.42 billion in 2023 to $6.68 billion by 2032, driven by AI-based modeling, regulatory support, and accelerated drug development strategies.
Certara launches AI-powered Quantitative Systems Pharmacology (QSP) platform called Certara IQ, highlighting the company's technological innovation in drug development. The company also celebrates its scientific achievements with 200 published papers and 11 scientists recognized among top cited researchers.
Certara, a biosimulation technology company, will release its third quarter 2025 financial results on November 6th, hosting a conference call at 5:00 PM ET for investors.
